AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03274297
Drug: EVRA patch (NGMN+EE) (Treatment A) (Reference)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single transdermal contraceptive patch of EVRA (NGMN + EE) containing 6 milligram (mg) of the progestin NGMN and 600 microgram (mcg) of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.
Trial: NCT03274297
Drug: HMW PIB patch (NGMN+EE) (Treatment B) (Test)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single transdermal contraceptive HMW PIB (NGMN + EE) patch containing 6 mg of the progestin NGMN and 600 mcg of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.
Trial: NCT03632213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group: 15 patients, both sexes, will receive oral placebo for 12 months.
Trial: NCT01699815
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02521415
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal (IN) fentanyl (1.5 micrograms/kg)
Trial: NCT02521415
Drug: ibuprofen or acetaminophen
RxNorm normalized name: acetaminophen / ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg of ibuprofen or 15 mg/kg of acetaminophen will be given to participants prior to the randomized intervention
Trial: NCT01867892
Drug: ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxapliplatin ,irinotecan ,5FU +leucovorin ,RT 5,040cGy in 28 fractions/5.5 wks and 5FU 450mg/m2 iv 30min weekly
Trial: NCT03962894
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During a sequenced rollout protocol change for several EMS agencies, those agencies will adopt protocol change to administer prednisolone to children with asthma attacks in the prehospital environment prior to ED arrival.
Trial: NCT03973229
Drug: Estradiol patch
RxNorm normalized name: Estradiol Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.
Trial: NCT04168892
Drug: 225 IU of HMG in patients with age > 35 years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.
Trial: NCT04205565
Drug: Placebo group: Placebo Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.
Trial: NCT03556592
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1x 100 mg tablet
Trial: NCT02281422
Drug: BIA 2-093
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03514108
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets x 3 daily
Trial: NCT03514108
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
Trial: NCT03761173
Drug: Anticoagulation Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation medication
Trial: NCT03713879
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rectally administered indomethacin before or after ERCP
Trial: NCT02864550
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxycycline 100mg orally daily
Trial: NCT04454866
Drug: Single injection of penehyclidine
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of penehyclidine hydrochloride (0.5 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
Trial: NCT04454866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of placebo (normal saline 5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
Trial: NCT01483924
Drug: Apo805K1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential parallel dose escalation.
Trial: NCT02017340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8mg Placebo tablet taken once a day at lunch time for 78 weeks
Trial: NCT02014714
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug: Fentanyl 40mcg Depending on the randomization schedule, 40μg of fentanyl will be added to the intrathecal mixture.
Trial: NCT02325492
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04148495
Drug: placebo of acetaminophen IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes (taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Placebo of acetaminophen IV: Sodium chloride 0.9%
Trial: NCT04148495
Drug: acetaminophen IV
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes ((taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Acetaminophen IV: 1 g
Trial: NCT02154763
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02045238
Drug: Hypertonic Saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Chloride 3% solution, previously prepared in 5 mL syringes.
Trial: NCT01311960
Drug: normal saline 0.9%
RxNorm normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline eye drop 0.9% will apply 4 times a day for 3 months.
Trial: NCT00739349
Drug: vehicle/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle/placebo
Trial: NCT00965432
Drug: STX107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of an oral suspension
Trial: NCT00737126
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of a daily tablet containing 5 mg of folic acid for 4 months.
Trial: NCT00737126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of an oral placebo pill
Trial: NCT01986465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02615574
Drug: CKM
RxNorm normalized name: BUCKMINSTERFULLERENE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one cycle of CKM alone followed by three cycles of vaccine + CKM.
Trial: NCT04435665
Drug: NFX-179 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel for topical administration
Trial: NCT04435665
Drug: Vehicle Gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle gel for topical administration
Trial: NCT04351867
Drug: docetaxel plus oxaliplatin and capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: docetaxel 50mg/㎡ ivgtt. d1+oxaliplatin 100mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d
Trial: NCT04351867
Drug: oxaliplatin plus capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oxaliplatin 130mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d
Trial: NCT00419263
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of placebo).
Trial: NCT01511848
Drug: DFP, DFO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Deferoxamine It will be administered subcutaneously over 8 hours for 5 days at a dose of 40 mg/kg.~Other Name: Desferal, DFO Drug: DFP DFP: will be orally administered at a dose of 75mg/kg orally in 3 divided doses for 7 days
Trial: NCT01383733
Drug: RO5458640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending doses intravenously, weekly or every 2 weeks or every 3 weeks
Trial: NCT01163097
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin continuous IV infusion
Trial: NCT03260166
Drug: nicotinamide
RxNorm normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: nicotinamide; Pharmaceutical form: tablet; Route of administration: oral
Trial: NCT01027000
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01027000
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04092270
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04092270
Drug: Peposertib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01297166
Drug: LEO 27989 ointment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once daily application, 3weeks
Trial: NCT04477629
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-experimental: CS is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at a dose no less than 5mg/d.
Trial: NCT02609048
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Capsule
Trial: NCT03777657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match tislelizumab IV on Day 1 of each 21-day cycle
Trial: NCT03777657
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m² orally twice daily (BD) Days 1 through 14 (14 days total) of each 21-day cycle
Trial: NCT01817192
Drug: Adjuvant Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who have undergone complete resection of NSCLC that has been documented histologically to be non-squamous and that is pathological Stage I or IIA, will undergo testing with the 14-Gene Prognostic Assay. Patients determined to be intermediate or high risk and who meet all eligibility criteria will be randomized either to observation or to four cycles of adjuvant therapy with a standard NSCLC platinum-based doublet.
Trial: NCT00259441
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00688818
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be initiated on 50 mg of Placebo and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.
Trial: NCT00726726
Drug: Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules + Tablets + Oral solution, Oral, Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg once daily, Day 1, 1 Day
Trial: NCT03494387
Drug: Antioxidants
RxNorm normalized name: E Complex with Antioxidants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidants versus placebo
Trial: NCT01261338
Drug: olestra
RxNorm normalized name: Beta Sitosterol/Campesterol/Stigmasterol 100 MG-50 MG-40 MG Oral Tablet [CHOLESTRATIN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-absorbable dietary fat
Trial: NCT04162873
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO or via feeding tube
Trial: NCT00566449
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one dose daily for 4 weeks
Trial: NCT04768101
Drug: [11C]-PIB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[11C\]-PIB is a PET radiotracer used to evaluate levels of Αβ burden.
Trial: NCT02666898
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PART 2 :~patients with BM MRD \>10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days Cyclophosphamide : 250 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and fludarabine
Trial: NCT03894215
Drug: AGEN1884
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTLA-4 antibody
Trial: NCT00980460
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00980460
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02673476
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo tablets
Trial: NCT02549352
Drug: LEO43204 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02549352
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02337985
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02337985
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04088227
Drug: Experimental Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive platelet rich plasma injection two times prior to surgery.
Trial: NCT02789605
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients of group B will took the placebo similarly at the Lactobacillus rhamnosus Lcr35® orally . All patients will be then followed up for 3 additional months without treatment.
Trial: NCT03858322
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.
Trial: NCT00646022
Drug: [18F]-DOPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-DOPA PET/CT Scan.
Trial: NCT00960219
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1# BID, oral, for 6 weeks
Trial: NCT03160885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains the same excipients, in the same concentration only lacking tralokinumab
Trial: NCT02928978
Drug: Placebo (for Ruxolitinib)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet (taken by mouth)
Trial: NCT03656081
Drug: inhaled placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled isotonic saline
Trial: NCT01347255
Drug: Daivobet® ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily application, 4 weeks
Trial: NCT04552873
Drug: Urea
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight)~If hyponatremia persists beyond D8 after initiation of the study treatment (urea or placebo), that is to say after the date of the collection of the primary endpoint, it will be possible to introduce corticosteroids (fludrocortisone or others). These treatments will be collated.~If during patient monitoring the serum sodium exceeds 145 mmol / L, treatment should no longer be administered.
Trial: NCT00570440
Drug: Oral contraceptives--ethinyl estradiol, levonorgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 visits - screening/enrollment, 6-months and 12 months
Trial: NCT03319940
Drug: CRS Mitigation Strategies
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be treated with one of the CRS mitigation strategies.
Trial: NCT04191096
Drug: Androgen Deprivation Therapy (ADT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.
Trial: NCT04041050
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule; Oral
Trial: NCT03663933
Drug: Immunosuppression Only Conditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E-ATG 40 mg/kg IV once daily for days -14 and -13. Prednisone: Tapering doses, given orally daily, and given prior to each daily dose of e-ATG on days -14 and -13 Pentostatin:4 mg/m2/day IV on days -9 and -5, cyclophosphamide:5 mg/kg orally daily on days -9 through -2
Trial: NCT03324425
Drug: Simvastatin 80mg
RxNorm normalized name: SIMVASTATIN 80MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive simvastatin 80 mg by mouth daily at bedtime
Trial: NCT04161755
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFIRINOX regimen will be administered 21 weeks post-tumor resection (+/- 2 weeks)
Trial: NCT04104139
Drug: Trifluridine and Tipiracil Hydrochloride
RxNorm normalized name: tipiracil / trifluridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03654716
Drug: ALRN-6924
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALRN-6924 is a drug that blocks certain proteins in tumor cells called MDM2 and MDMX. These proteins may be important in the growth of some cancers. Laboratory experiments and results from studies with adults show that ALRN-6924 may stop tumor growth and, in some cases, may cause tumor cells to die.
Trial: NCT04483115
Drug: TPN171H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets; Oral; Single dose
Trial: NCT04483115
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets; Oral; Single dose
Trial: NCT02180867
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02180867
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04002661
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT00775853
Drug: 6-[18F]Fluorodopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04705415
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
Trial: NCT03804372
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
Trial: NCT00870974
Drug: [18F]FPEB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of \[18F\]F-PEB
Trial: NCT00961792
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beverage containing 0.8 g/kg ethanol, 0.4 g/kg ethanol
Trial: NCT00961792
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beverage containing 0.0 g/kg alcohol to act as placebo
Trial: NCT00961792
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beverage containing the equivalent of 1.5 times the participant's daily caffeine intake
Trial: NCT03036462
Drug: Iron
RxNorm normalized name: Iron
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: i.v. iron administration